Provided By GlobeNewswire
Last update: Sep 6, 2023
ST. LOUIS, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Heart Centre Rigshospitalet of Copenhagen University Hospital successfully treated the first patients using Stereotaxis’ Genesis Robotic Magnetic Navigation System. The Genesis system is the latest and most advanced robotic technology available for the treatment of heart rhythm disorders. Rigshospitalet is among the first in Europe, and the only hospital in Denmark, to offer the Genesis system to patients.
NYSEARCA:STXS (5/9/2025, 11:10:48 AM)
2.175
+0.01 (+0.69%)
Find more stocks in the Stock Screener